Sophiris Bio Inc  

(Public, NASDAQ:SPHS)   Watch this stock  
Find more results for PINK:PTXRF
3.21
-0.08 (-2.43%)
Aug 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.15 - 3.28
52 week 2.10 - 5.91
Open 3.17
Vol / Avg. 21,025.00/26,687.00
Mkt cap 55.42M
P/E     -
Div/yield     -
EPS -1.56
Shares 16.84M
Beta     -
Inst. own     -
Aug 7, 2014
Q2 2014 Sophiris Bio Inc Earnings Release
More events from DailyFinance »    

Address

1258 Prospect Street
LA JOLLA, CA 92037
United States - Map
+1-858-7771760 (Phone)
+1-858-4125693 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Sophiris Bio, Inc., formerly Protox Therapeutics Inc., is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate). The Company has partnered with Kissei Pharmaceuticals for the development and commercialization of PRX302 in Japan. Sophiris Bio, Inc. is advancing a pipeline of receptor targeted fusion proteins based on three complementary technology platforms: PORxin, INxin and HUMxin. It focuses on diseases of the prostate via its PORxin platform candidate, PRX302, which has completed three clinical trials for the treatment of BPH, as well as two clinical trials for the treatment of localized recurrent prostate cancer.

Officers and directors

Lars Ekman M.D., Ph.D. Executive Chairman of the Board
Bio & Compensation  - Reuters
Randall E. Woods President, Chief Executive Officer, Director
Bio & Compensation  - Reuters
Peter T. Slover CPA Chief Financial Officer
Bio & Compensation  - Reuters
Allison J. Hulme Ph.D. Chief Operating Officer, Head - Research & Development
Bio & Compensation  - Reuters
Iain R. Mant Corporate Secretary
Bio & Compensation  - Reuters
Joseph L. Turner Jr. Director
Age: 61
Bio & Compensation  - Reuters
John Geltosky Ph.D. Independent Director
Bio & Compensation  - Reuters
James Heppell Independent Director
Bio & Compensation  - Reuters
William R. Rohn Independent Director
Age: 69
Bio & Compensation  - Reuters